DOCSLIB.ORG

Propofol and Benzodiazepine Modulation of Gaba,R Function

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Propofol and Benzodiazepine Modulation of Gaba,R Function PROPOFOL AND BENZODIAZEPINE MODULATION OF GABA,R FUNCTION Laura Catherine McAdam A thesis submitted in conformity with the requirements for the degree of Master of Science Graduate Department of Physiology University of Toronto G Copyright by Laura Catherine McAdam (1997) National Library Bibliothèque nationale m*m of Canada du Canada Acquisitions and Acquisitions et Bibliographic Senrices services bibliographiques 395 Wellington Street 395, rue Wellington Ottawa ON KIA ON4 ûttawa ON K 1 A ON4 Canada Canada Your Me Votre reIsrmœ Our Ne Noire reftirencB The author has granted a non- L'auteur a accordé une Licence non exclusive licence allowing the exclusive permettant à la National Library of Canada to Bibliothèque nationale du Canada de reproduce, han, distribute or sell reproduire, prêter, distribuer ou copies of tbis thesis in microform, vendre des copies de cette thèse sous paper or electronic formats. la forme de microfiche/film, de reproduction sur papier ou sur format électronique. The author retains ownership of the L'auteur conserve la propriété du copyright in this thesis. Neither the droit d'auteur qui protège cette thèse. thesis nor substantial extracts fkom it Ni la thèse ni des extraits substantiels may be printed or otherwise de celle-ci ne doivent être imprimés reproduced without the author's ou autrement reproduits sans son permission. autorisation. A. ABSTRACT PROPOFOL AND BENZODIAZEPM MODULATION OF GABAARFUNCTION Master of Science, 1997 Laura Catherine McAdam Department of Physiology, University of Toronto The general anaesthetic, propo fol, has multiple effects on the GABA,R: it potentiates GABA-evoked responses; it activates the receptor, and it alters the kinetics of receptor desensitization. In contrast, sedative benzodiazepines only potentiate GABA-evoked responses. It is not known if the multiple effects of propofol on the GABA,R are mediated by distinct binding sites or which effect accounts for propofol's anaesthetic properties. The whole-ceIl patch clamp method was used to study the effects of benzodiazepines and propofol on GABA,R's present in cultured, murine hippocarnpal neurons. The concentration of propofol that activated the GABA,R (EC,, = 24.3 k 3.4 PM) was significantly greaeater than that which decreased receptor desensitization (EC,, = 1.15 + 0.33 PM). Furthemore. midazolam potentiated propofol-induced currents but did not alter propofol- induced changes in receptor desensitization, suggesting that receptor activation and desensitization were mediated by distinct mechmisms. Low concentrations of propofol (1 PM) and midazolam (0.5 plu) interacted in a superadditive rnanner to enhance GABA (0.3 PM)-evoked responses and isobolographic analysis suggested a synergistic interaction. Ln contrast, higher concentrations of these dmgs produced an additive interaction. As low concentrations of propofol and midazolam interact synergistically to produce hypnosis and higher concentrations do not interact synergistically to induce anaesthesia, Our results suggest that hypnosis and anaesthesia may be mediated by distinct changes in GABAARhnction. B. ACKNOWLEDGMENTS 1 wish to express my sincere gratitude to my supervisors, Dr. B.A. Oner and Dr. J.F. MacDonald for their guidance and encouragement over the past two years. 1 would also like to thank Dr. Orser for introducing me to the clinical aspects of research and for the opportunities to visit Sunnybrook Health Science Centre. I also appreciate the advice provided by my cornmittee member, Dr. Wojtowicz. 1 would like to thank my labrnates for providing a stimulating, helphl and fnendly working atmosphere. I also gratefully acknowledge Lidia Brandes and Ella Czerwinska for overseeing the ce11 cultures. Finally, and most importantly. 1 would like to thank my parents and sisters for al1 of their love and support throughout the paçt Z years. This research was supported by an International Anesthetists Research Society Frontiers in Anesthesia Research Grant Award to Dr. Orser. C. TABLE OF CONTENTS -. A. ABSTRACT II -.. B. ACLN0WLEDGiMENTS 111 C. TABLE OF CONTENTS i v ... D. LIST OF FIGURES Vlll E. LIST OF TABLES i x F. ABBREVIATION NDEX X t NTRODUCTION .LVAESTHESIA NON-SPECIFIC AND SPECEIC THEORJES OF ANAESTHETIC ACTION NIBITORY NEUROTRANSMISSION AND GABA, RECEPTORS GABA GN3A,R PROPERTIES KMETIC MODEL OF GABA,R FUNCTION DESENSITIZATION SUBWTS OF THE GABA,R GABAARAND ANAESTHESIA PROPOFOL EFFECTS ON GABAAR BENZODIAZEPNE ACTION AT THE GABA,R 1 -4.1. BENZODIAZEPINE BWWG IS NFLüENCED BY SUBUNIT COMPOSITION OF THE GABA,+R 1.5. DRUG INTERACTIONS BETWEEN PROPOFOL AND BENZODIAZEPMS 1S. 1 DETERMNTNG DRUG NTERACTIONS -.7 OBJECTIVES AND WORKING HYPOTHESIS 3.1. SECTION 1 -.-.3 9 SECTION 3 LMETHODS CELL CULTURES RECORDNG PIPETTES PIPETTE SOLUTION WHOLE-CELL VOLTAGE-CLAMP RECORDINGS DRL'G Ai'AGONIST PERFUSION SYSTEM WHOLE-CELL CURRENT AYALYSIS DRUG INTERACTION ANALYSIS DRUGS AND OTHER CHEMICALS STATISTICS 4. RESC'LTS 4.1. SECTION 1 il.1.1. MIDAZOLAM MCREASED THE AFFNTY OF THE GABA,R FOR GABA -4ND PROPOFOL 37 3.1.2. MIDAZOLALM DOES NOT INFLUENCE DESENSITIZATION OF THE GABA,R 47 3.1.3. PROPOFOL DECREASED RECEPTOR DESENSITIZATION 50 4.1 .4. PROPOFOL-NUCED .MODULATION OF GABA,R 55 4.2. SECTION 2 64 3.1. EFFECTS OF MIDAZOLAM AND PROPOFOL ON CC'RREXTS EVOKED BY SUBSATURATNG CONCENTRATIONS OF GABA 64 1.2.2. SYNERGISTIC NI'ERACTION BETWEEN PROPOFOL AiÿD MIDAZOLAM IN THE PRESENCE OF LOW CONCENTR4TIONS OF GABA 77 5. DISCUSSION 88 5.1. SECTION 1 88 5.1.1. MIDAZOLAM POTENTUTION OF GABA-EVOKED CURRENTS 88 5.1.2. ,MIDAZOLAM POTENTlATION OF PROPOFOL-EVOKED Cb'RRENTS 89 5.1.3. PROPOFOL BLOCKA.DE OF THE GABA,,R 92 5 4 MID.LVOLAM DiD NOT I'CTLLT'YCE DESENSITIZ.4TIO-Y OF THE G.ABX,R 93 5.1 3. PROPOFOL MODLZXïION OF GrZBA,R DESENSITIZATIOX 94 3- .-.9 SECTION 2 97 5.1. PH.4K'.'ACOLOGICAL SYNERGISM BETWEEX PROPOFOL .%.ND 'tlIDAZOL-X.kl 97 5.2 CLiS1C.U SYXERGISM BETWEE'V PROPOFOL .k\D .MID=VOL.I.f 98 6. CONCLCSIONS -7. REFEREXCES D. LIST OF FIGURES GN3Aergic synapses and the topology of a G.4BA,R subunit ?/lultibarrel fast-perfusion system Desensitization of GABA induced currents Isobolographic anal ysis Midazolam increased the affinity of the GABA,R for GXBA .Midazolam increased the affinity of the GABA,R for propofol Midazolam potentiated currents evoked by propofol The W relationship of propofol-induced currents recorded in the absence and presence of midazolarn Midazolam did not influence GABA,R desensitization of the GABA,R for currents evoked by GABA .Midamlm did not aiter desensitization of propo fol-evoked currents Propo fo 1 decreased GN3A,R desensitization in a concentration-dependent mann er Midazo lam did not e ffect propo fol-induced modulation of GABA,R desensitization Midazolam did not influence GABA,R desensitization at lower concentrations of D~ODO~O~ Propofol and midazolam (or flurazepam) produced an additive enhancement of GABA (3 p.M)-evoked currents From hippocampal neurons 65 Widazolam and propofol did not alter the reversa1 potential of the GABA-evoked currents 68 Propofol and midazolam produced an additive enhancernent of GABA (3 pu)- evoked currents when the concentration of propofol was reduced 7 1 Propofol and midazolam produced a superadditive enhancement of G.4E5.4 (3 uM)-evoked currents when the concentration of GABA was reduced 73 Propofol and midazolam produced an additive enhancement of G.îB.4 (3~~34)- evoked currents in spinal cord neurons 'vlidazolam potentiation of GABA ( 1 ,uM)-evoked response Propofol potentiation of GABA ( 1 FM)-evoked response Propofol enhancement of currents evoked by co-application of midazolam and G.%l3-4 Synergisric interactions between propofol and midazolarn E. LIST OF TABLES 1. Propofoi increased the rate of GAB.4,R desensitization and deactivation at 56 saturating concentrations of GABA -7 - Widazolam increased the rate of GAB.A4R deactivation at two concentrations of 63 propofol in the presence of saturating concentrations of GM.4 F. .U3BREVIATION INDEX .MPA a-amino-3-hydroxyl-5-methyl-4-isoxazole propionic acid ATP adenosine-5-triphosphate BDZ benzodiazepine BZ 1 benzodiazepine type 1 BZ2 benzodiazepine type 2 CDPX chlordiazepoxide CNS central nenious system DMSO dimethyt sulfoxide DRC dose response curve EGO concentration that produces 50 % of the observed response EGTA ehylene glycol-0,0'-bis(2-aminoethy1)-N,N,N,N',N7-te~~cetcacid FLU flurazepam FMZ flumazenil G-proteins guanine nucleotide binding protein GABA 7-aminobutync acid GABA,R a subtype of y-arninobutyric acid receptor GABA,R a subtype of y-arninobutyric acid receptor GAi3bR a subtype of 7-aminobutyric acid receptor GAD glutamic acid decarboxylase HEPES 25 N-2-hydroxy-ethylpiperazine-N'-2-ethanesulphoic acid IC,, concentration that inhibits the response by 50 % IPSC inhibitory post-synaptic current KA kainate MDZ midazo larn MEM minimum essential media nAChR nicotinic acety lcholine recep tor NMDA N-methyl-D-aspartate 'CMDAR NMDA receptor PA p icoamperes PRO propo fol P s picosiemens TE,4 tetraethylarnrnonium TM transmembrane domain TTX tetrodotoxin 1. INTRODUCTION 1.1. ANAESTHESIA haesthesia is a complex phenornenon defined as a behavioural state associated with the loss of awareness and absence of pain (Tanelian. 1993). The mechanisms of dmg action that produce general anaesthesia are not well understood despite the use of these drugs for over 200 years (Harris et al.. 1995). It is commonly thought that general anaesthetics alter synaptic transmission rather than inhibit the propagation of impulses along the length of the nerve fiber (Franks and Lieb, 1994). Aithough some anaesthetics decrease the synthesis, uptake and release of neurotransmitters, evidence for major presynaptic target sites is minimal (Tanelian et al., 1993). Anaesthetics are thought to pnmady influence receptors present in the post-synaptic membrane (Franks and Lieb. 1994). The y-aminobutyric acid type,, receptor (GABA,R) is thought to play an important role in mediating the behavioural effects of intravenous anaesthetics including propofol. barbiturates, several neuroactive steroids and sedative benzodiazepines (Franks and Lieb.
Load more

Recommended publications
  • Drug & Alcohol Testing Program
    Pottawattmie County Drug & Alcohol Testing Program Appendix A Table of Contents POLICY STATEMENT ...................................................................................................................................... 3 SCOPE ............................................................................................................................................................ 4 EDUCATION AND TRAINING .......................................................................................................................... 4 DESIGNATED EMPLOYER REPRESENTATIVE (DER): ....................................................................................... 5 DUTY TO COOPERATE ................................................................................................................................... 5 EMPLOYEE ADMISSION OF ALCOHOL AND CONTROLLED SUBSTANCE USE: (49 CFR Part 382.121) ... 6 PROHIBITED DRUGS AND ILLEGALLY USED CONTROLLED SUBSTANCES: ..................................................... 7 PROHIBITED BEHAVIOR AND CONDUCT: ...................................................................................................... 8 DRUG & ALCOHOL TESTING REQUIREMENTS (49 CFR, Part 40 & 382) ............................................... 10 DRUG & ALCOHOL TESTING CIRCUMSTANCES (49 CFR Part 40 & 382) .............................................. 12 A. Pre-Employment Testing: .................................................................................................... 12 B. Reasonable Suspicion Testing: .........................................................................................
    [Show full text]
  • Analgesia and Sedation in Hospitalized Children
    Analgesia and Sedation in Hospitalized Children By Elizabeth J. Beckman, Pharm.D., BCPS, BCCCP, BCPPS Reviewed by Julie Pingel, Pharm.D., BCPPS; and Brent A. Hall, Pharm.D., BCPPS LEARNING OBJECTIVES 1. Evaluate analgesics and sedative agents on the basis of drug mechanism of action, pharmacokinetic principles, adverse drug reactions, and administration considerations. 2. Design an evidence-based analgesic and/or sedative treatment and monitoring plan for the hospitalized child who is postoperative, acutely ill, or in need of prolonged sedation. 3. Design an analgesic and sedation treatment and monitoring plan to minimize hyperalgesia and delirium and optimize neurodevelopmental outcomes in children. INTRODUCTION ABBREVIATIONS IN THIS CHAPTER Pain, anxiety, fear, distress, and agitation are often experienced by GABA γ-Aminobutyric acid children undergoing medical treatment. Contributory factors may ICP Intracranial pressure include separation from parents, unfamiliar surroundings, sleep dis- PAD Pain, agitation, and delirium turbance, and invasive procedures. Children receive analgesia and PCA Patient-controlled analgesia sedatives to promote comfort, create a safe environment for patient PICU Pediatric ICU and caregiver, and increase patient tolerance to medical interven- PRIS Propofol-related infusion tions such as intravenous access placement or synchrony with syndrome mechanical ventilation. However, using these agents is not without Table of other common abbreviations. risk. Many of the agents used for analgesia and sedation are con- sidered high alert by the Institute for Safe Medication Practices because of their potential to cause significant patient harm, given their adverse effects and the development of tolerance, dependence, and withdrawal symptoms. Added layers of complexity include the ontogeny of the pediatric patient, ongoing disease processes, and presence of organ failure, which may alter the pharmacokinetics and pharmacodynamics of these medications.
    [Show full text]
  • Safe Injection Practices for Administration of Propofol
    Safe Injection Practices for Administration of Propofol CECIL A. KING, MS, RN; MARY OGG, MSN, RN, CNOR ABSTRACT Sepsis and postoperative infection can occur as a result of unsafe practices in the administration of propofol and other injectable medications. Investigations of infec- tion outbreaks have revealed the causes to be related to bacterial growth in or contamination of propofol and unsafe medication practices, including reuse of syringes on multiple patients, use of single-use medication vials for multiple pa- tients, and failure to practice aseptic technique and adhere to infection control practices. Surveys conducted by AORN and other researchers have provided addi- tional information on perioperative practices related to injectable medications. In 2009, the US Food and Drug Administration and the Centers for Disease Control and Prevention convened a group of clinicians to gain a better understanding of the issues related to infection outbreaks and injectable medications. The meeting participants proposed collecting data to persuade clinicians to adopt new practices, developing guiding principles for propofol use, and describing propofol-specific, site-specific, and practitioner-specific injection techniques. AORN provides resources to help perioperative nurses reduce the incidence of postoperative infection related to med- ication administration. AORN J 95 (March 2012) 365-372. © AORN, Inc, 2012. doi: 10.1016/j.aorn.2011.06.009 Key words: sterile injectable medications, propofol, sepsis, safe injection prac- tices, safe medication
    [Show full text]
  • Statement on Safe Use of Propofol 2019
    Statement on Safe Use of Propofol Committee of Origin: Ambulatory Surgical Care (Approved by the ASA House of Delegates on October 27, 2004, and amended on October 23, 2019) Because sedation is a continuum, it is not always possible to predict how an individual patient will respond. Due to the potential for rapid, profound changes in sedative/anesthetic depth and the lack of antagonist medications, agents such as propofol require special attention. Even if moderate sedation is intended, patients receiving propofol should receive care consistent with that required for deep sedation. The Society believes that the involvement of an anesthesiologist in the care of every patient undergoing anesthesia is optimal. However, when this is not possible, non-anesthesia personnel who administer propofol should be qualified to rescue* patients whose level of sedation becomes deeper than initially intended and who enter, if briefly, a state of general anesthesia.** • The physician responsible for the use of sedation/anesthesia should have the education and training to manage the potential medical complications of sedation/anesthesia. The physician should be proficient in airway management, have advanced life support skills appropriate for the patient population, and understand the pharmacology of the drugs used. The physician should be physically present throughout the sedation and remain immediately available until the patient is medically discharged from the post procedure recovery area. • The practitioner administering propofol for sedation/anesthesia should, at a minimum, have the education and training to identify and manage the airway and cardiovascular changes which occur in a patient who enters a state of general anesthesia, as well as the ability to assist in the management of complications.
    [Show full text]
  • Aminobutyric Acid Type a and Glycine Receptors Influences Their Sensitivity to Propofol
    PERIOPERATIVE MEDICINE A Single Phenylalanine Residue in the Main Intracellular Loop of ␣1 ␥-Aminobutyric Acid Type A and Glycine Receptors Influences Their Sensitivity to Propofol Gustavo Moraga-Cid, Ph.D.,* Gonzalo E. Yevenes, Ph.D.,* Gu¨ nther Schmalzing, M.D.,† Robert W. Peoples, Ph.D.,‡ Luis G. Aguayo, Ph.D.§ Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/115/3/464/254366/0000542-201109000-00010.pdf by guest on 02 October 2021 ABSTRACT What We Already Know about This Topic • Propofol positively modulates receptors for the inhibitory Background: The intravenous anesthetic propofol acts as a transmitters ␥-aminobutyric acid type A (GABA) and glycine, positive allosteric modulator of glycine (GlyRs) and ␥-ami- but the molecular mechanisms involved are unclear nobutyric acid type A (GABAARs) receptors. Although the role of transmembrane residues is recognized, little is known about the involvement of other regions in the modulatory What This Article Tells Us That Is New effects of propofol. Therefore, the influence of the large in- • A single homologous residue in the large M3-M4 intracellular tracellular loop in propofol sensitivity of both receptors was ␣ loops of the 1 subunits of GABAA and glycine receptors mod- explored. ulates the action of propofol but not of other general anesthetics ␣ ␣ ␤ Methods: The large intracellular loop of 1 GlyRs and 1 2 GABAARs was screened using alanine replacement. Sensitiv- ity to propofol was studied using patch-clamp recording in 80 Ϯ 23%). Remarkably, propofol-hyposensitive mutant re- HEK293 cells transiently transfected with wild type or mu- ceptors retained their sensitivity to other allosteric modula- tant receptors.
    [Show full text]
  • Pentameric Ligand-Gated Ion Channel ELIC Is Activated by GABA And
    Pentameric ligand-gated ion channel ELIC is activated PNAS PLUS by GABA and modulated by benzodiazepines Radovan Spurnya, Joachim Ramerstorferb, Kerry Pricec, Marijke Bramsa, Margot Ernstb, Hugues Nuryd, Mark Verheije, Pierre Legrandf, Daniel Bertrandg, Sonia Bertrandg, Dennis A. Doughertyh, Iwan J. P. de Esche, Pierre-Jean Corringerd, Werner Sieghartb, Sarah C. R. Lummisc, and Chris Ulensa,1 aDepartment of Cellular and Molecular Medicine, Laboratory of Structural Neurobiology, Catholic University of Leuven, 3000 Leuven, Belgium; bDepartment of Biochemistry and Molecular Biology of the Nervous System, Medical University of Vienna, A-1090 Vienna, Austria; cDepartment of Biochemistry, University of Cambridge, Cambridge CB2 1QW, United Kingdom; dPasteur Institute, G5 Group of Channel-Receptor, Centre National de la Recherche Scientifique, 75724 Paris, France; eDepartment of Medicinal Chemistry, VU University Amsterdam, 1081 HV, Amsterdam, The Netherlands; fSOLEIL Synchrotron, 91192 Gif sur Yvette, France; gHiQScreen, CH-1211 Geneva, Switzerland; and hCalifornia Institute of Technology, Pasadena, CA 91125 Edited* by Jean-Pierre Changeux, Institut Pasteur, Paris Cedex 15, France, and approved September 10, 2012 (received for review May 24, 2012) GABAA receptors are pentameric ligand-gated ion channels in- marized in SI Appendix, Table S1). In addition, it has been volved in fast inhibitory neurotransmission and are allosterically suggested that the GABA carboxylate group is stabilized through modulated by the anxiolytic, anticonvulsant, and sedative-hypnotic electrostatic interactions with Arg residues on the principal and benzodiazepines. Here we show that the prokaryotic homolog ELIC complementary faces of the binding site (4, 7–9). For benzo- also is activated by GABA and is modulated by benzodiazepines diazepines, the individual contributions of residues in loops A–F with effects comparable to those at GABAA receptors.
    [Show full text]
  • Differential Actions of Ethanol and Trichloroethanol at Sites in the M3 and M4 Domains of the NMDA Receptor Glun2a (NR2A) Subunit AK Salous Marquette University
    Marquette University e-Publications@Marquette Biomedical Sciences Faculty Research and Biomedical Sciences, Department of Publications 11-1-2009 Differential Actions of Ethanol and Trichloroethanol at Sites in the M3 and M4 Domains of the NMDA Receptor GluN2A (NR2A) Subunit AK Salous Marquette University H Ren Marquette University KA Lamb Marquette University Xiang-Qun Hu Marquette University, [email protected] RH Lipsky George Mason University See next page for additional authors Accepted version. British Journal of Pharmacology, Vol. 158, No. 5 (November 2009): 1395–1404. DOI. © 2009 Wiley. Used with permission. This is the peer reviewed version of the following article: "Differential Actions of Ethanol and Trichloroethanol at Sites in the M3 and M4 Domains of the NMDA Receptor GluN2A (NR2A) Subunit," which has been published in final form here: DOI. This article may be used for non- commercial purposes in accordance With Wiley Terms and Conditions for self-archiving. Authors AK Salous, H Ren, KA Lamb, Xiang-Qun Hu, RH Lipsky, and Robert W. Peoples This article is available at e-Publications@Marquette: https://epublications.marquette.edu/biomedsci_fac/95 NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be accessed by following the link in the citation at the bottom of the page. Differential Actions of Ethanol and Trichloroethanol at Sites in the M3 and M4 Domains of the NMDA Receptor GluN2A (NR2A) Subunit AK Salous Department of Biomedical Sciences, Marquette University Milwaukee, WI H. Ren Department of Biomedical Sciences, Marquette University Milwaukee, WI KA Lamb Department of Biomedical Sciences, Marquette University Milwaukee, WI X-Q Hu Department of Biomedical Sciences, Marquette University Milwaukee, WI RH Lipsky Department of Neuroscience, INOVA Fairfax Hospital Falls Church, VA Krasnow Institute for Advanced Study, George Mason University Fairfax, VA RW Peoples Department of Biomedical Sciences, Marquette University Milwaukee, WI British Journal of Pharmacology, Vol.
    [Show full text]
  • Clinical Trial of the Neuroprotectant Clomethiazole in Coronary Artery Bypass Graft Surgery a Randomized Controlled Trial Robert S
    Anesthesiology 2002; 97:585–91 © 2002 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc. Clinical Trial of the Neuroprotectant Clomethiazole in Coronary Artery Bypass Graft Surgery A Randomized Controlled Trial Robert S. Kong, F.R.C.A.,* John Butterworth, M.D.,† Wynne Aveling, F.R.C.A.,‡ David A. Stump, M.D.,† Michael J. G. Harrison, F.R.C.P.,§ John Hammon, M.D.,ʈ Jan Stygall, M.Sc.,# Kashemi D. Rorie, Ph.D.,** Stanton P. Newman, D.Phil.†† Background: The neuroprotective property of clomethiazole THE efficacy of coronary artery bypass surgery in the has been demonstrated in several animal models of global and relief of angina and in some circumstances in enhancing Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/97/3/585/335909/0000542-200209000-00011.pdf by guest on 29 September 2021 focal brain ischemia. In this study the authors investigated the life expectation is now accepted. It is a tribute to the low effect of clomethiazole on cerebral outcome in patients under- mortality of the procedure that interest is now focused going coronary artery bypass surgery. Methods: Two hundred forty-five patients scheduled for on the neurologic and neuropsychological complica- 1–3 coronary artery bypass surgery were recruited at two centers tions. Adverse neurologic outcomes have been found and prospectively randomized to clomethiazole edisilate to occur in 2–6% of patients and neuropsychological (0.8%), 225 ml (1.8 mg) loading dose followed by a maintenance deficits in 10–30%.4–6 These complications are consid- dose of 100 ml/h (0.8 mg/h) during surgery, or 0.9% NaCl ered to be ischemic in nature, being a consequence of (placebo) in a double-blind trial.
    [Show full text]
  • Halogenated Ether, Alcohol, and Alkane Anesthetics Activate TASK-3 Tandem Pore Potassium Channels Likely Through a Common Mechanism S
    Supplemental material to this article can be found at: http://molpharm.aspetjournals.org/content/suppl/2017/03/21/mol.117.108290.DC1 1521-0111/91/6/620–629$25.00 https://doi.org/10.1124/mol.117.108290 MOLECULAR PHARMACOLOGY Mol Pharmacol 91:620–629, June 2017 Copyright ª 2017 by The American Society for Pharmacology and Experimental Therapeutics Halogenated Ether, Alcohol, and Alkane Anesthetics Activate TASK-3 Tandem Pore Potassium Channels Likely through a Common Mechanism s Anita Luethy, James D. Boghosian, Rithu Srikantha, and Joseph F. Cotten Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts (A.L., J.D.B., and J.F.C.); Department of Anesthesia, Kantonsspital Aarau, Aarau, Switzerland (A.L.); Carver College of Medicine, University of Iowa, Iowa City, Iowa (R.S.) Received January 7, 2017; accepted March 20, 2017 Downloaded from ABSTRACT The TWIK-related acid-sensitive potassium channel 3 (TASK-3; hydrate (165% [161–176]) . 2,2-dichloro- . 2-chloro 2,2,2- KCNK9) tandem pore potassium channel function is activated by trifluoroethanol . ethanol. Similarly, carbon tetrabromide (296% halogenated anesthetics through binding at a putative anesthetic- [245–346]), carbon tetrachloride (180% [163–196]), and 1,1,1,3,3,3- binding cavity. To understand the pharmacologic requirements for hexafluoropropanol (200% [194–206]) activate TASK-3, whereas molpharm.aspetjournals.org TASK-3 activation, we studied the concentration–response of the larger carbon tetraiodide and a-chloralose inhibit. Clinical TASK-3 to several anesthetics (isoflurane, desflurane, sevoflurane, agents activate TASK-3 with the following rank order efficacy: halothane, a-chloralose, 2,2,2-trichloroethanol [TCE], and chloral halothane (207% [202–212]) .
    [Show full text]
  • Pharmacokinetics of Propofol Administered by Target- Controlled Infusion to Alcoholic Patients Frédérique S
    Anesthesiology 2003; 99:576–85 © 2003 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc. Pharmacokinetics of Propofol Administered by Target- controlled Infusion to Alcoholic Patients Frédérique S. Servin, M.D.,* Bernard Bougeois, M.D.,* Roberto Gomeni, Ph.D.,† France Mentré, M.D., Ph.D.,‡ Robert Farinotti, Ph.D.,§ Jean-Marie Desmonts, M.D.ʈ Background: Chronic alcoholic patients are frequently pre- require larger doses of “anesthetic agents,” even in the sented for anesthesia and surgery. These patients require absence of withdrawal symptoms. Although it is com- higher doses of propofol than control patients for induction of monly recommended that the dose of thiopental should anesthesia, but whether this is because of changes in pharma- cokinetics or pharmacodynamics is not known. This study was be increased in alcoholic patients, no pharmacokinetic designed to investigate the influence of chronic ethanol intake or pharmacodynamic changes could be demonstrated in Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/99/3/576/337574/0000542-200309000-00012.pdf by guest on 26 September 2021 on propofol pharmacokinetics. chronic alcoholic patients.2 Moreover, unnecessarily Methods: Fifteen chronic alcoholic and 15 control patients, high doses may be deleterious in this population in receiving propofol by target-controlled infusion for otolaryn- whom alcohol-related cardiac disease is frequent.3 In gologic surgery, were studied. Blood propofol concentrations 4 were measured at regular intervals during and after the propo- addition to sporadic case reports, a prospective study fol infusion. Nonlinear mixed-effects population models (NON- has shown that the induction dose of propofol was MEM) examining the influence of alcoholism were constructed.
    [Show full text]
  • Pharmacological Treatments in Insomnia
    Pharmacological treatments in insomnia Sue Wilson Centre for Neuropsychopharmacology, Division of Brain Sciences, Imperial College, London Drugs used in insomnia Licensed for insomnia •GABA-A positive allosteric modulators •melatonin (modified release) •promethazine •diphenhydramine •doxepin (USA) Unlicensed prescribed frequently •antihistamines (and OTC) •antidepressants Sometimes prescribed drugs for psychosis Some GABA-A positive allosteric modulators Drugs acting at the GABA-A benzodiazepine receptor zopiclone zolpidem zaleplon benzodiazepines eg temazepam, lorazepam (safe in overdose, as long as no other drug involved) Drugs acting at the barbiturate/alcohol receptor chloral hydrate/chloral betaine clomethiazole (dangerous in overdose) GABA calms the brain Gamma aminobutyic acid (GABA) is the main inhibitory transmitter in the mammalian central nervous system. It plays the principal role in reducing neuronal excitability and its receptors are prolific throughout the brain, in cortex, limbic system, thalamus and cerebellum sedative Increase anticonvulsant GABA anxiolytic function ataxia, memory effects Effects of GABA-A positive allosteric modulators •These drugs enhance the effect of GABA, the main inhibitory neurotransmitter in the brain •They all produce sedation, sleep promotion, ataxia, muscle relaxation, effects on memory, anticonvulsant effects •Therefore for insomnia the duration of action of the drug is important – these effects are unwanted during the day Effects of these GABA-ergic drugs on sleep EEG/PSG • Appearance of
    [Show full text]
  • A New Pharmacokinetic Model of Propofol for Japanese Patients
    Open Journal of Anesthesiology, 2019, 9, 179-188 https://www.scirp.org/journal/ojanes ISSN Online: 2164-5558 ISSN Print: 2164-5531 A New Pharmacokinetic Model of Propofol for Japanese Patients Masahito Omote, Shunsuke Tachibana, Yasuyuki Tokinaga* , Michiaki Yamakage Department of Anesthesiology, Sapporo Medical University School of Medicine, Sapporo, Japan How to cite this paper: Omote, M., Ta- Abstract chibana, S., Tokinaga, Y. and Yamakage, M. (2019) A New Pharmacokinetic Model Target-controlled infusion (TCI) of propofol is used for general anesthesia. of Propofol for Japanese Patients. Open However, the only pharmacokinetic parameter commercially used for Japa- Journal of Anesthesiology, 9, 179-188. nese patients is weight, and pharmacokinetic models are based on European https://doi.org/10.4236/ojanes.2019.99017 physical attributes. Drug metabolism also differs in races. This study aimed to Received: August 25, 2019 identify optimal continuous doses of propofol for Japanese patients and to Accepted: September 16, 2019 create a simulated pharmacokinetic (PK) model. Thirty Japanese patients Published: September 19, 2019 were enrolled. Patients received a constant infusion of 9 mg/kg/h of propo- Copyright © 2019 by author(s) and fol. Arterial blood samples were collected and the time course of plasma Scientific Research Publishing Inc. propofol concentrations was modeled using the nonlinear mixed effects This work is licensed under the Creative model (NONMEM) three-compartmental PK model. We validated the model Commons Attribution International License (CC BY 4.0). by intravenously injecting 10 patients with a TCI driver system programmed http://creativecommons.org/licenses/by/4.0/ with the NONMEM model. Our model’s performance was evaluated using Open Access the median prediction error (MDPE), median absolute prediction error (MDAPE), and Wobble.
    [Show full text]